Xalatamax eye drops 0.005% 2.5ml

Xalatamax eye drops - is an antiglaucoma drug. The active substance is an analog of prostaglandin and basically increases the amount of fluid leaking. As a result, the severity of intraocular hypertension is reduced. The effect lasts up to 24 hours.

Antiglaucoma preparation for topical application. Latanoprost is an analogue of prostaglandin F2α and a selective agonist of FP-receptors. Reduces intraocular pressure by increasing the outflow of aqueous humor and has anti-glaucoma effect. The main mechanism of action of latanoprost is associated with an increase in uveoscleral outflow. Does not have a significant effect on the production of aqueous humor and does not affect the hemato-ophthalmic barrier.

Decrease in intraocular pressure begins 3-4 hours after the administration of the drug, the maximum effect is observed after 8-12 hours, the duration of action is not less than 24 hours.

Pharmacokinetics

Suction

It penetrates well through the cornea, with the hydrolysis of latanoprost to the biologically active form - latanoprost acid. Cmax of latanoprost in aqueous humor is achieved approximately 2 hours after topical application of the preparation.

In the eye tissues, latanoprost acid is not practically metabolized; metabolism occurs mainly in the liver.

Metabolism and excretion

T1 / 2 is 17 minutes. The main metabolites - 1,2-dinor- and 1,2,3,4-tetranor metabolites do not possess or have weak biological activity, are excreted by the kidneys.

Indications:

• Open angle glaucoma.
• Increased intraocular pressure.

Contraindications:

• Individual hypersensitivity to latanoprost, benzalkonium chloride or other components of the drug;
• age to 18 years.

Special instructions:

Latanoprost can cause a gradual change in eye color due to an increase in the amount of brown pigment in the iris. This effect is mainly seen in patients with mixed iris color, for example, blue-brown, gray-brown, green-brown or yellow-brown, which is explained by an increase in melanin in the stromal melanocytes of the iris. Typically, brown pigmentation spreads concentrically around the pupil to the periphery of the iris of the eyes, while the entire iris or parts of it can acquire a more intense brown color. Patients with uniformly colored eyes of blue, gray, green or brown color change eye color after two years of use of the drug were very rare. The color change is not accompanied by any clinical symptoms or pathological changes. After the drug was discontinued, there was no further increase in the amount of brown pigment, but the already developed color change may be irreversible. In the presence of nevi or lentigo on the iris, their changes were not observed under the influence of therapy.

Latanoprost can cause gradual changes in eyelashes and fleece hair, such as lengthening, thickening, increased pigmentation, increased density and a change in the direction of growth of eyelashes. The eyelash changes are reversible and pass after the cessation of treatment. Before starting treatment, patients should be informed about the possibility of changing eye color. In the case of an intensive change in eye pigmentation, treatment may be discontinued. Treatment of only one eye can lead to permanent heterochromia. The drug contains benzalkonium chloride, which can be absorbed in contact lenses. If contact lenses are used, they should be removed before instillation and re-dressed no earlier than 15-20 minutes after the instillation of the drug.

Impact on the ability to drive vehicles and manage mechanisms

Patients who, after application of eye drops, have a transient fogging of vision, it is not recommended to drive or work with moving mechanisms until it is restored. The bottle must be closed after each use. Do not touch the tip of the pipette to the eye.

Suggested Use:

The drug is buried in the conjunctival eye bag 1 drop once a day in the evening.

When skipping the dose, the next one is administered in the usual mode (i.e., the dose is not doubled).

With more frequent administration of the drug, its effectiveness decreases.

The duration of the course of treatment and the possibility of its recurrence are determined by the doctor.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!